What is the price of Timber Pharmaceuticals, Inc. (TMBR)

The price of Timber Pharmaceuticals, Inc. (TMBR) is $0.0101

What is the market cap of Timber Pharmaceuticals, Inc. (TMBR)

The market cap of Timber Pharmaceuticals, Inc. (TMBR) is $5.32K

Timber Pharmaceuticals, Inc. (TMBR) EPS

Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.

Year	EPS	Change
Not enough data for the provided dates.

Year

EPS

Change

Not enough data for the provided dates.

Company	EPS	EPS Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$13.70	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Company

EPS

EPS Difference

Country